Healthcare / BiotechnologyNasdaqCM
$2.07
-0.11 (-5.05%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-162.4M · quality 48.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$919M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-46.8%
↓Gross Margin
99.4%
↑Debt/Equity
0.58
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
+10.1%
FCF CAGR
—
FCF margin
-136.2%
FCF / Net income
1.35x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $49.8M · net income $-50.3M · FCF $-67.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $49.8M | $49.8M | $31.1M | $1.2M | $139000.00 | $0.00 | $23.4M | $32.3M | $26.6M | $15.9M | $0.00 | $130.0M | $22.9M | $2.2M | $1.1M | $1.8M | $4.9M | $10.7M |
| Net Income | $-50.3M | $-50.3M | $-200.4M | $-177.1M | $-101.9M | $-87.8M | $-58.6M | $130.1M | $-120.5M | $-123.0M | $-131.4M | $-4.7M | $-100.3M | $-104.1M | $-110.2M | $-116.2M | $-101.8M | $-82.8M |
| EBITDA | $-41.4M | $-41.4M | $-184.3M | $-163.5M | $-98.7M | $-86.8M | $-44.9M | $145.1M | $-99.6M | $-127.2M | $-125.1M | $2.2M | $-98.4M | $-99.5M | $-104.2M | $-109.2M | $-90.3M | $-83.8M |
| EPS | — | — | -0.63 | -0.79 | -0.62 | -0.60 | -0.53 | 1.16 | -1.14 | -1.17 | — | — | — | — | — | — | — | — |
| Gross Margin | 99.4% | 99.4% | 98.0% | 92.9% | 100.0% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -98.2% | -98.2% | -634.2% | -14265.0% | -72489.2% | — | -204.2% | 437.5% | -388.5% | -822.1% | — | 1.1% | -439.2% | -4607.2% | -9955.5% | -6170.6% | -1950.2% | -840.7% |
| Net Margin | -101.1% | -101.1% | -644.8% | -14710.9% | -73341.0% | — | -250.3% | 402.5% | -453.5% | -774.0% | — | -3.6% | -438.8% | -4686.1% | -10120.4% | -6285.3% | -2073.7% | -773.6% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.58 | 0.58 | 0.74 | 1.14 | 0.47 | 0.00 | 0.00 | 2.00 | -9.24 | 3.39 | 0.51 | 0.35 | 0.31 | 0.12 | 0.08 | 0.08 | 0.11 | — |
| Current Ratio | 18.80 | 18.80 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-67.9M | $-67.9M | $-179.8M | $-162.4M | $-90.2M | $-88.2M | $-143.1M | $113.7M | $-148.7M | $-185.6M | $-175.9M | $183.9M | $-75.7M | $-92.8M | $-95.0M | $-89.1M | $-83.5M | $-89.4M |
| Returns | ||||||||||||||||||
| ROE | -46.8% | -46.8% | -137.3% | -190.2% | -87.0% | -77.3% | -37.5% | 111.1% | 456.5% | -180.2% | -78.5% | -1.6% | -35.3% | -61.2% | -41.3% | -39.1% | -41.2% | — |
| Valuation | ||||||||||||||||||
| P/B | 7.00 | 7.00 | 1.73 | 3.51 | 3.03 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | 60.2% | 60.2% | 2481.5% | 766.2% | — | -100.0% | -27.6% | 21.6% | 67.3% | — | -100.0% | 468.9% | 928.5% | 104.0% | -41.1% | -62.3% | -54.1% | — |
| EPS Growth | — | — | 20.3% | -27.4% | — | -13.2% | -145.7% | 201.8% | 2.6% | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+228.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.63 → n/d
Residual
+228.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.